Frederico Thiago Nouer, da Silva Freitas Tiago
Singular Pain Clinic, Campinas, Brazil.
Brasilia Pain Institute and Hospital Sírio Libanês, Brasilia, Brazil.
Pain Med. 2020 Aug 1;21(Suppl 1):S18-S26. doi: 10.1093/pm/pnaa201.
Upper limb complex regional pain syndrome is an important cause of chronic pain, and its treatment is challenging. In this pilot case series, we preliminarily evaluated the feasibility, effectiveness, and safety of a new technique for brachial plexus neuromodulation in the treatment of this disease in patients refractory to conservative treatment.
Between 2017 and 2018, 14 patients considered to be refractory to optimized conservative treatment were recruited to this study. In the first stage, patients were trialed for seven days with a new technique of implant of the brachial plexus. Patients with ≥50% pain relief in visual analog scale (VAS) score received a definitive implantation in the second stage. Follow-ups were conducted at pre-implant and 12 months using the Neuropathic Pain Scale, SF-32, and the visual analogic scale for pain.
After the initial trial, 10 patients had a pain reduction of ≥50% and received a permanent implant. At 12-month follow-up, VAS, Neuropathic Pain Scale, SF-12 physical and mental scores improved by 57.4% +/- 10% (P = 0.005), 60.2% +/- 12.9% (P = 0.006), and 21.9% +/- 5.9% (P = 0.015), respectively.
Our data suggest that this new technique of brachial plexus stimulation may have long-term utility in the treatment of painful upper limb complex regional pain syndrome. New more detailed comprehensive studies should be carried out to confirm our findings in a larger population and to further refine the clinical implementation of this technique.
上肢复杂性区域疼痛综合征是慢性疼痛的重要原因,其治疗具有挑战性。在这个前瞻性病例系列中,我们初步评估了一种臂丛神经调节新技术在治疗保守治疗无效的该病患者中的可行性、有效性和安全性。
2017年至2018年,14例被认为对优化保守治疗无效的患者被纳入本研究。在第一阶段,采用臂丛神经植入新技术对患者进行为期7天的试验。视觉模拟量表(VAS)评分疼痛缓解≥50%的患者在第二阶段接受确定性植入。在植入前和12个月时使用神经病理性疼痛量表、SF-32和疼痛视觉模拟量表进行随访。
初始试验后,10例患者疼痛减轻≥50%并接受了永久性植入。在12个月的随访中,VAS、神经病理性疼痛量表、SF-12身体和心理评分分别改善了57.4%±10%(P = 0.005)、60.2%±12.9%(P = 0.006)和21.9%±5.9%(P = 0.015)。
我们的数据表明,这种臂丛神经刺激新技术在治疗疼痛性上肢复杂性区域疼痛综合征方面可能具有长期效用。应开展更详细的综合研究,以在更大规模人群中证实我们的发现,并进一步完善该技术的临床应用。